Objective response rate · people with metastatic breast cancer
Capecitabine‐containing regimens showed no clear difference in objective response rate compared with chemotherapy regimens without capecitabine (moderate certainty).
1 finding from 1 review
Quality of life · people with metastatic breast cancer
1 finding from 1 review
Pathological complete response · neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
Capecitabine‐containing regimens showed no clear difference in pathological complete response (pCR): breast and axillary nodes compared with non‐capecitabine‐containing regimens (high certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Capecitabine showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (moderate certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
It is very uncertain whether capecitabine changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
1 finding from 1 review
Time to progression · people with advanced gastric cancer
It is very uncertain whether capecitabine changes time to progression compared with 5‐FU‐containing regimens (very low certainty).
1 finding from 1 review
Progression‐free survival · people with advanced gastric cancer
It is very uncertain whether capecitabine changes progression‐free survival compared with 5‐FU‐containing regimens (very low certainty).
1 finding from 1 review
Treatment‐related death · people with advanced gastric cancer
It is very uncertain whether capecitabine changes treatment‐related death compared with 5‐FU‐containing regimens (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
Capecitabine showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus mitomycin C changes all‐cause mortality at 1 year compared with capecitabine plus mitomycin C (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus mitomycin C changes overall response rate compared with capecitabine plus mitomycin C (very low certainty).
1 finding from 1 review
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grade 1 ‐ 4 thrombocytopenia · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus mitomycin C changes grade 1 ‐ 4 thrombocytopenia compared with capecitabine plus mitomycin C (very low certainty).
1 finding from 1 review